(MedPage Today) — The investigational GLP-1 receptor agonist MET-097i, which may be able to be dosed just once a month, yielded weight loss of up to 14.1% by week 28 with class-leading tolerability in a phase IIb trial, said developer Metsera…
Source link : https://www.medpagetoday.com/endocrinology/generalendocrinology/117716
Author :
Publish date : 2025-09-30 18:19:00
Copyright for syndicated content belongs to the linked Source.
